TM inhibitors, short for Transmembrane Inhibitors, represent a diverse and important category of chemical compounds that primarily target cellular processes involving the transmembrane proteins. These inhibitors exert their effects by modulating the function of transmembrane proteins, which are integral components of the cell membrane responsible for a wide array of biological functions, such as signal transduction, ion transport, and cell adhesion. Transmembrane proteins span the lipid bilayer of the cell membrane, with regions embedded within the hydrophobic core and portions extending into the extracellular and intracellular spaces. TM inhibitors are specifically designed to disrupt or regulate the activity of these proteins, thus influencing critical cellular functions.
TM inhibitors encompass a broad range of chemical structures and mechanisms of action. Some TM inhibitors function by binding to specific transmembrane proteins and altering their conformation, preventing them from carrying out their normal functions. Others may interfere with the assembly or trafficking of transmembrane proteins within the cell, disrupting their localization and function. Additionally, certain TM inhibitors can modulate the permeability of the cell membrane itself, affecting the transport of ions, nutrients, or other molecules across the lipid bilayer. The diverse nature of TM inhibitors allows for their application in various research contexts, such as cell biology, molecular pharmacology, and drug discovery, where they serve as invaluable tools for elucidating the roles of transmembrane proteins in cellular processes.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Inhibits the BCR-ABL kinase, blocking tyrosine phosphorylation and signaling in chronic myeloid leukemia cells. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Targets the epidermal growth factor receptor (EGFR), disrupting downstream signaling pathways in cancer cells. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Blocks EGFR kinase activity, hindering proliferation and survival of cancer cells. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Inhibits multiple kinases, including RAF and VEGFR, disrupting cell proliferation and angiogenesis in cancer. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Targets multiple receptor tyrosine kinases, including VEGFR and PDGFR, inhibiting angiogenesis and tumor growth. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Blocks BCR-ABL and SRC kinases, impeding the growth of leukemia cells and other malignancies. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Inhibits both EGFR and HER2 tyrosine kinases, interfering with the growth of HER2-positive breast cancer cells. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
Targets BCR-ABL kinase, preventing tyrosine phosphorylation and the proliferation of leukemia cells. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $175.00 $983.00 | 2 | |
Blocks BCR-ABL and other tyrosine kinases, offering therapeutic options for resistant forms of leukemia. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Inhibits VEGFR, EGFR, and RET kinases, impacting angiogenesis and signaling in thyroid cancer. | ||||||